Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

thday. Children born prematurely as well as those with CLD or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups such as the elderly, those with underlying respiratory or cardiac disease, and those with compromised immune systems (e.g., bone marrow transplant patients).

About Motavizumab

Motavizumab is an investigational humanized MAb being evaluated for its potential to prevent serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease. Phase 1 and Phase 2 study data have been reported showing that motavizumab appears to have a similar safety and pharmacokinetic profile to Synagis in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract.

About Synagis

Synagis is the only MAb approved by the U.S. Food and Drug Administration (FDA) to help prevent an infectious disease. Since its licensure in 1998, Synagis has been administered to more than 1,000,000 infants in the U.S. and has become the standard of care for infants at high risk for RSV. Synagis is indicated for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease, which is prominent in the Northern Hemisphere during the winter months. Synagis is a humanized MAb given by an intramuscular injection once a month during the RSV season. Synagis was approved in 1998 by the FDA; in 1999, by the European Medicines Evaluation Agency; and in 2002, by the Japanese Ministry of Health, Labor and Welfare. In 2003, the FDA expanded the U.S. label for Synagis for use in young children with hemodynamically significant CHD at risk of RSV disease. To date, Synagis has been approved in 62 countries, including the United States. Synagis is indicated for the prevention of serious lower respiratory t
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/19/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on ... is a professional and in-depth market survey ... The report firstly reviews the basic information ... and manufacturing technology. The report then explores ... Hydrochloride listing their product specification, capacity, Production ...
(Date:9/19/2014)... , September 19, 2014 ... has announced the addition of the ... to their offering.      (Logo: ... been broadly classified into wide categories based ... for the treatment of different gynecological conditions ...
(Date:9/19/2014)... According to the new ... therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, ... Global Forecast to 2019" published by MarketsandMarkets, the global ... Million by 2019 from $14,240.0 Million in 2014, ... 2019. Browse 74 market data tables ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... Inc. is pleased,to announce the dosing of the first ... study of AEG35156, a second generation antisense,therapeutic targeting XIAP, ... The study, made possible, in part, by funding ... 1-2, Multicenter, Open-Label Study,of the X- Linked Inhibitor of ...
... July 30 Anpath Group, Inc.,(OTC Bulletin Board: ... Inc. (ESI) announced that its EnviroTru(R),disinfectant has been ... Services (DMS) in the State of Florida. The ... LLC(TM) ( http://www.aworldofgreen.com ),worked with the ...
Cached Medicine Technology:Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156 2Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156 3Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 2Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 3
(Date:9/21/2014)... Discount-Dress.com, a company that specializes ... its decision to implement a new shopping cart software ... across the world. Furthermore, the company has unveiled a ... , The new items come in fashionable designs; all ... to 56 percent off. "We are happy to release ...
(Date:9/21/2014)... High in the rugged Gore Range ... able-bodied athletes rafted the Colorado River, rode mountain bikes ... pursuit of outdoor adventure. At the September 12-14 ... Sports, disabilities proved to be no more than an ... stage event. , Each participating team of five athletes ...
(Date:9/21/2014)... 21, 2014 Recently, BambooIndustry.com, an experienced ... offer for its bamboo panels ( http://www.bambooindustry.com/products/bamboo-panel/ ). The ... all of them are available at discounted prices now, ... company’s discounted bamboo panels are available in ... quality materials. Each of them is finely manufactured by ...
(Date:9/21/2014)... According to latest National Vital Statistics Reports ... 1966 (10.5 births per 1,000 women in 2013). Since 2000, ... steadily by 2 percent per year. The birth rate for ... and over) also rose, the first such increase since 2008. ... times as many first births to women aged 35 and ...
(Date:9/20/2014)... (PRWEB) September 21, 2014 Diabetes ... Kenneth Pullman that is helping thousands of people learn ... symptoms without shots, pills, or prescriptions has caught the ... , “There are currently tens of millions of people ... 1 and Type 2 diabetes, and unfortunately, big pharma ...
Breaking Medicine News(10 mins):Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3Health News:Discounted Bamboo Panels For Sale At BambooIndustry.com 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2
... (ACP) today commended Congress for taking bipartisan action to ... by stabilizing physician payments through 2011. The College ... to enact legislation to provide longer-term stability in payments ... (SGR) formula. The legislation, passed unanimously ...
... News) -- There,s no scientific evidence that stricter testing ... federal food and nutrition programs would improve the safety ... Council report released Thursday. The authors based their ... Agriculture,s Agricultural Marketing Service,s (AMS) program, which is used ...
... Kathleen Doheny HealthDay Reporter , THURSDAY, Dec. ... drugs often prescribed to breast cancer patients, may ... according to a Canadian researcher. ,There have always ... Princess Margaret Hospital in Toronto, who is scheduled to ...
... new study shows that a new type of targeted ... good as surgery for patients aged 75 and older ... the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This ... Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), ...
... of the children,s television show Sesame Street, had improved ... by researchers at the Johns Hopkins Bloomberg School of ... had the greatest exposure to Jalan Sesama improved significantly ... social awareness, compared to those with no or low ...
... MI 9 December, 2010 The 19th International ... (CPMRC), an Elsevier company and leader in assisting healthcare ... focus on transformational leadership and feature advice from many ... Visa, Inc.. "The essence of transformation, real ...
Cached Medicine News:Health News:ACP commends Congress for preserving patient access by stopping scheduled Medicare SGR cuts 2Health News:No Scientific Proof Backing Stricter Tests of Ground Beef in School Lunches 2Health News:Certain Breast Cancer Drugs Linked With Heart Risks in Older Women 2Health News:Certain Breast Cancer Drugs Linked With Heart Risks in Older Women 3Health News:Non-invasive SRT as good as surgery for elderly patients with early lung cancer 2Health News:Sesame Street program improves development for children in Indonesia 2Health News:Transformation at top of agenda for CPMRC's annual conference in Jan. 2011 2
Post-Surgical compression garments...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... that quantitatively measure two important cardiac risk ... serum or plasma homocysteine level is increasingly ... factor for cardiovascular disease. And numerous studies ... levels of Lp(a) with increased risk of ...
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
Medicine Products: